Loading viewer...
investor_presentation
Format: PDF investor_presentation
Enochian Biosciences presents its enhanced gene and cell therapy pipeline designed to leverage immune response against cancer and infectious diseases. The Nasdaq-listed company, headquartered in Los Angeles, outlines its clinical development strategy and funding position with approximately $79.4M raised to date and a pending $100M S-3 shelf registration.
investor_presentation
22 Pages
Hawkins, Inc.
investor_presentation
DZ BANK Group